Dopa-responsive dystonia

Toby C Yaltho MD (Dr. Yaltho of Methodist Sugar Land Neurology Associates received honorariums from Allergan for speaking engagements.)
Joseph Jankovic MD, editor. (Dr. Jankovic, Director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine, received research funding from Allergan, Allon, Ceregene, Chelsea, EMD Serono, Impax, Ipsen, Lundbeck, Medtronic, Merz, and Teva, and compensation for his services as a consultant or an advisory committee member by Allergan, Auspex, EMD Serono, Lundbeck, Merz, Neurocrine Biosciences, and Teva.)
Originally released July 16, 1993; last updated December 21, 2016; expires December 21, 2019

Overview

Dopa-responsive dystonia is a genetically heterogeneous syndrome that typically presents in children as leg dystonia and parkinsonism. Similar to juvenile-onset Parkinson disease, dopa-responsive dystonia is due to dopamine depletion, but unlike Parkinson disease, dopamine deficiency arises secondary to a defect in neurotransmitter synthesis rather than a loss of dopaminergic neurons. In this article, the author reviews the cardinal features, diagnosis, pathophysiology, treatment, and differential diagnosis of dopa-responsive dystonia, including related disorders of neurotransmitter metabolism.

Key points

 

• Dopa-responsive dystonia is a syndrome that typically presents in children as leg dystonia and parkinsonism.

 

• Dopa-responsive dystonia is a genetically heterogeneous disorder that can be inherited in either an autosomal dominant or autosomal recessive fashion.

 

• The most common pattern of dopa-responsive dystonia inheritance is autosomal dominant, and the majority of affected families have a mutation in the (GTP cyclohydrolase1) gene, GCH1.

 

• Dopa-responsive dystonia responds dramatically to low-dose levodopa therapy, independent of patient age or disease duration.

Historical note and terminology

The first description of dystonia specifically responsive to levodopa was provided in 1971 by Segawa (Segawa et al 1971). In the midst of the excitement of Parkinson disease treatment with levodopa, Segawa reported several young girls with prominent diurnal variation of dystonia whose symptoms were ameliorated with low-dose levodopa (Segawa et al 1976). Subsequent reports described families whose members had dystonia and parkinsonism that improved markedly following levodopa treatment. Further studies have distinguished dopa-responsive dystonia from young-onset Parkinson disease with dystonia and have clarified the genetic basis of the disorder. Among the inherited forms of secondary dystonia, dopa-responsive dystonia or hereditary progressive dystonia with diurnal variation (HPD) is classified as DYT5, a “dystonia-plus syndrome,” because of its association with other neurologic features (ie, parkinsonism), although evidence of neurodegeneration is lacking (Fahn et al 1998).

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.